ES2067866T3 - Reactivos inmunologicos que reaccionan con un epitopo constante del virus inmunodeficiente humano del tipo i (vih-1)gp120 y metodos de utilizacion. - Google Patents

Reactivos inmunologicos que reaccionan con un epitopo constante del virus inmunodeficiente humano del tipo i (vih-1)gp120 y metodos de utilizacion.

Info

Publication number
ES2067866T3
ES2067866T3 ES91304840T ES91304840T ES2067866T3 ES 2067866 T3 ES2067866 T3 ES 2067866T3 ES 91304840 T ES91304840 T ES 91304840T ES 91304840 T ES91304840 T ES 91304840T ES 2067866 T3 ES2067866 T3 ES 2067866T3
Authority
ES
Spain
Prior art keywords
hiv
virus type
react
methods
celulas
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES91304840T
Other languages
English (en)
Inventor
David Da-I Ho
James Edmun Robinson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cedars Sinai Medical Center
Louisiana State University and Agricultural and Mechanical College
Original Assignee
Cedars Sinai Medical Center
Louisiana State University and Agricultural and Mechanical College
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US07/701,129 external-priority patent/US5798251A/en
Application filed by Cedars Sinai Medical Center, Louisiana State University and Agricultural and Mechanical College filed Critical Cedars Sinai Medical Center
Application granted granted Critical
Publication of ES2067866T3 publication Critical patent/ES2067866T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70514—CD4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • C07K16/1036—Retroviridae, e.g. leukemia viruses
    • C07K16/1045—Lentiviridae, e.g. HIV, FIV, SIV
    • C07K16/1063—Lentiviridae, e.g. HIV, FIV, SIV env, e.g. gp41, gp110/120, gp160, V3, PND, CD4 binding site
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/461—Igs containing Ig-regions, -domains or -residues form different species
    • C07K16/462—Igs containing a variable region (Fv) from one specie and a constant region (Fc) from another
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Virology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • AIDS & HIV (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Cell Biology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

LA INVENCION SE REFIERE A INMUNOREACTIVOS QUE NEUTRALIZAN EL VIRUS DE INMUNODEFICIENCIA HUMANA TIPO 1 (HIV-1) AL ENLAZARSE A UN NUEVO EPITOPE CONSERVADO DEL HIV OREACTIVOS PRESENTAN UN AMPLIO EFECTO NEUTRALIZADOR A LA UNION DEL HIV A CELULAS RECEPTORAS Y SON POR LO TANTO UTILES EN LA DETECCION, PREVENCION, MEJORA Y TRATAMIENTO DE LA ENFERMEDAD PRODUCIDA POR EL HIV, PRINCIPALMENTE EL SIDA (SINDROME DE INMUNODEFICIENCIA ADQUIRIDA) Y EL ARC (COMPLEJO RELACIONADO CON EL SIDA). DE MANERA MAS PARTICULAR, LA INVENCION SE REFIERE A NUEVOS ANTICUERPOS MONOCLONALES HUMANOS SELECTIVAMENTE REACTIVOS A UN DETERMINANTE DEPENDIENTE DE LA CONFORMACION CONSERVADA DEL HIV-1 GP120, DERIVADOS DE LOS MISMOS, LINEAS DE CELULAS QUE PRODUCEN ESTOS ANTICUERPOS Y EL USO DE ANTICUERPOS MONOCLONALES Y SUS DERIVADOS PARA LA DETECCION, PREVENCION, MEJORA Y TRATAMIENTO DE LA ENFERMEDAD RELACIONADA CON EL HIV.
ES91304840T 1990-05-29 1991-05-29 Reactivos inmunologicos que reaccionan con un epitopo constante del virus inmunodeficiente humano del tipo i (vih-1)gp120 y metodos de utilizacion. Expired - Lifetime ES2067866T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US53085090A 1990-05-29 1990-05-29
US07/701,129 US5798251A (en) 1990-05-29 1991-05-16 Antibody and antibody derivative immunoreagents reactive with a conserved epitope of Human Immunodeficiency Virus Type 1 (HIV-1) gp 120

Publications (1)

Publication Number Publication Date
ES2067866T3 true ES2067866T3 (es) 1995-04-01

Family

ID=27063388

Family Applications (1)

Application Number Title Priority Date Filing Date
ES91304840T Expired - Lifetime ES2067866T3 (es) 1990-05-29 1991-05-29 Reactivos inmunologicos que reaccionan con un epitopo constante del virus inmunodeficiente humano del tipo i (vih-1)gp120 y metodos de utilizacion.

Country Status (12)

Country Link
US (2) US6054284A (es)
EP (2) EP0614985A1 (es)
JP (1) JP2792733B2 (es)
AP (1) AP237A (es)
AT (1) ATE115189T1 (es)
AU (2) AU643285B2 (es)
DE (1) DE69105627T2 (es)
DK (1) DK0459779T3 (es)
ES (1) ES2067866T3 (es)
GR (1) GR3015269T3 (es)
OA (1) OA09499A (es)
WO (1) WO1991018928A1 (es)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AP237A (en) * 1990-05-29 1993-04-29 Cedars Sinai Medical Center Immunoreagents reactive with a conserved epitope of human immunodeficiency virus type 1 (HIV-1) gp120 and methods of use.
US5346989A (en) * 1990-08-22 1994-09-13 Syntello Vaccine Development Kb Peptides for use in induction of T cell activation against HIV-1
WO1992005800A1 (en) * 1990-09-27 1992-04-16 Syntello Vaccin Development Kb Peptides for use in vaccination and induction of neutralizing antibodies against human immunodeficiency virus
JPH06502539A (ja) * 1990-10-26 1994-03-24 ザ・パブリック・ヘルス・リサーチ・インスティチュート・オブ・ザ・シティ・オブ・ニューヨーク・インコーポレーテッド Ｈｉｖ−１　ｇｐ１２０のｖ３ループおよびｃｄ−４結合部位に特異的な中和ヒトモノクローナル抗体
WO1992021377A1 (en) * 1991-06-03 1992-12-10 Syntello Inc. Peptides for use in induction of t cell activation against hiv-1
US6261558B1 (en) 1993-10-19 2001-07-17 The Scripps Research Institute Synthetic human neutralizing monoclonal antibodies to human immunodeficiency virus
US5843882A (en) 1995-04-27 1998-12-01 The United States Of America As Represented By The Department Of Health And Human Services Antiviral proteins and peptides
US6193982B1 (en) 1995-04-27 2001-02-27 The United States Of America As Represented By The Department Of Health & Human Services Anti-cyanovirin antibody with an internal image of gp120, a method of use thereof, and a method of using a cyanovirin to induce an immune response to gp120
US6780847B2 (en) 1995-04-27 2004-08-24 The United States Of America As Represented By The Department Of Health And Human Services Glycosylation-resistant cyanovirins and related conjugates, compositions, nucleic acids, vectors, host cells, methods of production and methods of using nonglycosylated cyanovirins
US6987096B1 (en) 1995-04-27 2006-01-17 The United States Of America As Represented By The Department Of Health And Human Services Antiviral proteins and peptides, DNA coding sequences therefor, and uses thereof
US6428790B1 (en) 1995-04-27 2002-08-06 The United States Of America As Represented By The Secretary Department Of Health And Human Services Cyanovirin conjugates and matrix-anchored cyanovirin and related compositions and methods of use
US7048935B2 (en) 1995-04-27 2006-05-23 The United States Of America As Represented By The Department Of Health And Human Services Cyanovirin conjugates and matrix-anchored cyanovirin and related compositions and methods of use
ES2299276T3 (es) 1998-12-31 2008-05-16 Novartis Vaccines And Diagnostics, Inc. Polipeptidos env del vih modificados.
EP1141314A2 (en) 1998-12-31 2001-10-10 Chiron Corporation Polynucleotides encoding antigenic hiv type c polypeptides, polypeptides and uses thereof
AU2002254382B2 (en) 2001-03-22 2007-02-15 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Glycosylation-resistant and nonglycosylated cyanovirins
CA2452015C (en) 2001-07-05 2012-07-03 Chiron Corporation Polynucleotides encoding antigenic hiv type c polypeptides, polypeptides and uses thereof
US20030170614A1 (en) 2001-08-31 2003-09-11 Megede Jan Zur Polynucleotides encoding antigenic HIV type B polypeptides, polypeptides and uses thereof
US20050014230A1 (en) * 2003-07-16 2005-01-20 Ccl Holding Co., Ltd. Preparation of fully human antibodies
EP2255832A3 (en) 2004-06-16 2011-02-09 Affinergy, Inc. IFBM's to promote attachment of target analytes
CN101313216A (zh) * 2005-09-22 2008-11-26 普洛茨股份有限公司 酵母突变体中产生的糖基化多肽及其使用方法
US20110212119A1 (en) * 2008-10-31 2011-09-01 Proteonova, Inc. Methods for making hiv vaccines and related compositions
CA2793959C (en) 2010-03-25 2019-06-04 Oregon Health & Science University Cmv glycoproteins and recombinant vectors
HUE037408T2 (hu) 2011-06-10 2018-08-28 Univ Oregon Health & Science CMV glikoproteinek és rekombináns vektorok
AU2012216792A1 (en) 2011-09-12 2013-03-28 International Aids Vaccine Initiative Immunoselection of recombinant vesicular stomatitis virus expressing HIV-1 proteins by broadly neutralizing antibodies
EP2586461A1 (en) 2011-10-27 2013-05-01 Christopher L. Parks Viral particles derived from an enveloped virus
ES2631608T3 (es) 2012-06-27 2017-09-01 International Aids Vaccine Initiative Variante de la glicoproteína Env del VIH-1
US20150065381A1 (en) 2013-09-05 2015-03-05 International Aids Vaccine Initiative Methods of identifying novel hiv-1 immunogens
US10058604B2 (en) 2013-10-07 2018-08-28 International Aids Vaccine Initiative Soluble HIV-1 envelope glycoprotein trimers
EP3069730A3 (en) 2015-03-20 2017-03-15 International Aids Vaccine Initiative Soluble hiv-1 envelope glycoprotein trimers
EP3072901A1 (en) 2015-03-23 2016-09-28 International Aids Vaccine Initiative Soluble hiv-1 envelope glycoprotein trimers

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS59116230A (ja) * 1982-11-29 1984-07-05 ベイロ−・カレツジ・オヴ・メデイスン ウイルス性感染因子に対する免疫応答を生起する抗−イデイオタイプ抗体
US4536479A (en) * 1983-03-22 1985-08-20 E. I. Du Pont De Nemours And Company Use of anti-idiotype antibodies in immunoassays
AU609447B2 (en) * 1987-02-19 1991-05-02 Nissin Shokuhin Kabushiki Kaisha Methods and materials for hiv detection and therapy
US5215913A (en) * 1987-11-30 1993-06-01 Roger Williams General Hospital IgG-1 human monoclonal antibody reactive with an HIV-1 antigen and methods of use
EP0349645A4 (en) * 1987-12-15 1991-11-27 Nippon Shokubai Kagaku Kogyo Co. Ltd. Photo-setting composition
WO1989005821A1 (en) * 1987-12-21 1989-06-29 Arch Development Corporation Hiv-related antigens and antibodies
EP0434713B1 (en) * 1988-09-13 1994-10-12 Chiron Corporation Hiv-1 envelope muteins lacking hypervariable domains
JPH0768276B2 (ja) * 1989-04-25 1995-07-26 タノックス バイオシステムズ インコーポレイテッド Ｈｉｖのｃｄ４結合領域に特異的な抗体
EP0493508A1 (en) * 1989-09-22 1992-07-08 Idec Pharmaceuticals Corporation Novel peptides associated with the cd4 binding region of gp120 and their methods of use
AP237A (en) * 1990-05-29 1993-04-29 Cedars Sinai Medical Center Immunoreagents reactive with a conserved epitope of human immunodeficiency virus type 1 (HIV-1) gp120 and methods of use.
US5798251A (en) * 1990-05-29 1998-08-25 Cedars-Sinai Medical Center Antibody and antibody derivative immunoreagents reactive with a conserved epitope of Human Immunodeficiency Virus Type 1 (HIV-1) gp 120
GB9013566D0 (en) * 1990-06-18 1990-08-08 Shell Int Research Process for producing gasoline components
KR920000333A (ko) * 1990-06-18 1992-01-29 챨스 엠. 브룩 HIV gp120 모노클로날 항체

Also Published As

Publication number Publication date
AP9100280A0 (en) 1991-07-31
DE69105627T2 (de) 1995-04-20
EP0614985A1 (en) 1994-09-14
AU7803591A (en) 1991-12-05
JPH05500818A (ja) 1993-02-18
OA09499A (en) 1992-11-15
GR3015269T3 (en) 1995-06-30
AU660574B2 (en) 1995-06-29
US6054284A (en) 2000-04-25
AP237A (en) 1993-04-29
US6190871B1 (en) 2001-02-20
ATE115189T1 (de) 1994-12-15
EP0459779A1 (en) 1991-12-04
AU643285B2 (en) 1993-11-11
EP0459779B1 (en) 1994-12-07
JP2792733B2 (ja) 1998-09-03
DK0459779T3 (da) 1995-05-29
AU5510794A (en) 1994-04-28
WO1991018928A1 (en) 1991-12-12
DE69105627D1 (de) 1995-01-19

Similar Documents

Publication Publication Date Title
ES2067866T3 (es) Reactivos inmunologicos que reaccionan con un epitopo constante del virus inmunodeficiente humano del tipo i (vih-1)gp120 y metodos de utilizacion.
ES2194015T3 (es) Anticuerpos monoclonales humanos neutralizantes del virus de inmunodeficiencia humana.
ATE405679T1 (de) Synthetische humane neutralisierende monoklonale antikörper gegen hiv
ATE122237T1 (de) Hiv-1 neutralisierende monoklonale antikörper.
DK0512112T3 (da) Anti-CD4-antistoffer, som blokerer HIV-inducerede syncytier
DK0589004T4 (da) Fremgangsmåde til bestemmelse af peptider, som hörer til immunologisk vigtige epitoper af HCV
NO169844C (no) Htlv-iii (env)-peptider
ATE135743T1 (de) Monoklonale menschliche antikörper gegen hiv-i
ES2139607T3 (es) Anticuerpos monoclonales contra las proteinas e2/ns1 supuestas vhc y procedimientos de utilizacion de estos anticuerpos.
DE69332911T2 (de) Rekombinanter humanisierter Antikörper gegen menschlichen Immunschwächevirus
FI931393A (fi) Peptider foer anvaendning vid vaccinering och induktion av neutraliserande motkroppar mot humant immunbristvirus
ES2066887T3 (es) Anticuerpo monoclonal para diferenciar individuos seropositivos hiv-2 de los hiv-1.
ES2147195T3 (es) Metodo para la deteccion de anticuerpos en individuos seronegativos.
ATE151078T1 (de) Verfahren und zwischenprodukte synthetischer antikörperderivate
BRPI9709524B8 (pt) processo para a produção de um anticorpo para células t que expressam cd4
ES2059577T3 (es) Fragmentos genicos que codifican para las regiones variables de un anticuerpo anti-hiv, anticuerpos anti-hiv quimericos expresados utilizando los mismos y procedimiento para su preparacion.
FI861966A (fi) Renad och tre gaonger klonad hepatit-a-virus.
ES2132115T3 (es) Anticuerpos monoclonales contra el virus de la hepatitis c y su procedimiento de utilizacion.
KR920000333A (ko) HIV gp120 모노클로날 항체
OA09634A (fr) Antigenes de la glycoproteine transmembranaire d'enveloppe d'un retrovirus humain du type HIV-2 antigenes presentant avec eux une parente immunologique
DE68926454D1 (de) Gegen hiv 1 gp48 spezifische antikörper
ATE134649T1 (de) Arzneimittel und verfahren zur behandlung von erworbenem immundefizienzsyndrom (aids) und aids- verwandtem komplex unter verwendung von karbohydratspezifischen antikörpern
ES2060162T3 (es) Utilizacion de los anticuerpos monoclonales anti-b2 microglobulina.
AR001840A1 (es) Composiciones y métodos para detectar y tratar el sindrome de inmunodeficiencia adquirida
ATE126238T1 (de) Monoklonale antikörper gegen gag-protein- vorläufer-p55 von hiv-virus.

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 459779

Country of ref document: ES